UK Markets closed

4SC AG (0R6U.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
1.56500.0000 (0.00%)
At close: 08:00AM GMT


Fraunhoferstrasse 22
Planegg 82152
49 89 700 763 0

Full-time employees22

Key executives

NameTitlePayExercisedYear born
Dr. Jason Loveridge B.Sc, B.Sc., FRSM, Ph.D.Chairman of Management Board, CEO & MD519kN/AN/A
Ms. Anna Niedl Ph.D.Corp. Communications & Investor Relations OfficerN/AN/AN/A
Dr. Susanne Danhauser-Riedl M.D.Chief Medical OfficerN/AN/AN/A
Ms. Larissa StuttemTeam AssistantN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs in Germany. Its products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase Ib/II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. The company also out-licenses its products to pharma and biotech companies for the treatment of cancer. It has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. The company was founded in 1997 and is headquartered in Planegg, Germany.

Corporate governance

4SC AG’s ISS governance QualityScore as of 1 October 2022 is 8. The pillar scores are Audit: 6; Board: 9; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.